Arlene V. Drack
About
In The Last Decade
Arlene V. Drack
117 papers receiving 3.9k citations
Peers
Comparison fields: 5 of 115
- Molecular Biology 2.4k
- Ophthalmology 2.1k
- Radiology, Nuclear Medicine and Imaging 1.0k
- Genetics 610
- Cellular and Molecular Neuroscience 497
Countries citing papers authored by Arlene V. Drack
This map shows the geographic impact of Arlene V. Drack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arlene V. Drack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arlene V. Drack more than expected).
Fields of papers citing papers by Arlene V. Drack
This network shows the impact of papers produced by Arlene V. Drack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arlene V. Drack. The network helps show where Arlene V. Drack may publish in the future.
Co-authorship network of co-authors of Arlene V. Drack
This figure shows the co-authorship network connecting the top 25 collaborators of Arlene V. Drack. A scholar is included among the top collaborators of Arlene V. Drack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arlene V. Drack. Arlene V. Drack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 5 | |
| 3 | 5 | |
| 4 | 0 | |
| 5 | 8 | |
| 6 | 9 | |
| 7 | 10 | |
| 8 | 5 | |
| 9 | Five-Year Post-Injection Results of the Phase 3 Trial of Voretigene Neparvovec-rzyl in Biallelic RPE65 Mutation-Associated Inherited Retinal Disease | 3 |
| 10 | Retinal degeneration in BBS10 mice is ameliorated by subretinal gene replacement | 1 |
| 11 | Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene | 3 |
| 12 | 30 | |
| 13 | 2 | |
| 14 | Distinct profiles of abnormal ganglion cell activity in two forms of Leber’s congenital amaurosis (LCA): Implications for therapy | 1 |
| 15 | Overcoming the overexpression toxicity of gene replacement therapy for Bardet Biedl Syndrome type 1 | 2 |
| 16 | Is TRPM1 associated Congenital Stationary Night Blindness stationary | 1 |
| 17 | 107 | |
| 18 | 15 | |
| 19 | 22 | |
| 20 | 100 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.